Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
Ofri Mosenzon(Hebrew University of Jerusalem), Itamar Raz(Hebrew University of Jerusalem), Deepak L. Bhatt(Mount Sinai Hospital), Anna Maria Langkilde(AstraZeneca (Sweden)), Thomas A. Zelniker(Medical University of Vienna), Ilan Yanuv(Hebrew University of Jerusalem), Erica L. Goodrich(Brigham and Women's Hospital), Marc S. Sabatine(Brigham and Women's Hospital), Hiddo J.L. Heerspink(University Medical Center Groningen), John Wilding(University of Liverpool), Aliza Rozenberg(Hebrew University of Jerusalem), Avivit Cahn(Hebrew University of Jerusalem), Peter A. Johansson(AstraZeneca (Sweden)), Jamie P. Dwyer(University of Utah), Darren K. McGuire(Parkland Health & Hospital System), Lawrence A. Leiter(St. Michael's Hospital), Sabina A. Murphy(Brigham and Women's Hospital), Martin Fredriksson(AstraZeneca (Sweden)), Eri Kato(Kyoto University Hospital), Stephen D. Wiviott(Thrombolysis in Myocardial Infarction Study Group), Ingrid Gause‐Nilsson(Thrombolysis in Myocardial Infarction Study Group)
Cited by 673
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k